Effectiveness of acupoint hot compress on early puerperal rehabilitation of parturients after natural childbirth: study protocol for a prospective, multi-center, randomized controlled clinical trial

Yuhang Zhu 1, Aihua Zhang 1, Chang Liu 2, Nicola Robinson 3, Myeong Soo Lee 4, Xiaoyang Hu 5, Hye Won Lee 4, Rong Zhang 6, 7, 8, 9, Fan Qu 1, 8

1. Women’s Hospital, School of Medicine, Zhejiang University, 310006 Hangzhou, Zhejiang, China
2. The Second Clinical Medical College of Zhejiang Chinese Medical University, 310053 Hangzhou, Zhejiang, China
3. School of Health and Social Care, London South Bank University, SE1 0AA London, UK
4. Korea Institute of Oriental Medicine, 34054 Daejeon, Republic of Korea
5. Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, SO16 5ST Southampton, UK
6. Neuroscience Research Institute, Peking University, 100191 Beijing, China
7. Department of Neurobiology, School of Basic Medical Sciences, Peking University, 100191 Beijing, China
8. Key Laboratory for Neuroscience, Ministry of Education of China, Neuroscience Research Institute, 100191 Beijing, China
9. Key Laboratory of Neuroscience, National Committee of Health and Family Planning of China, 100191 Beijing, China

*Correspondence: syqufan@zju.edu.cn (Fan Qu)

DOI: 10.31083/j.ceog4806214
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Submitted: 26 April 2021 Revised: 24 June 2021 Accepted: 1 July 2021 Published: 15 December 2021

Background: Early puerperal rehabilitation can interfere with a woman’s ability to care for herself and her infant. Acupoint hot compress, with a combination of acupoints and natural physical agent heat, has significant potential to alleviate symptoms experienced during early puerperium. Current evidence regarding the effects of acupoint hot compress therapy on early puerperal rehabilitation is insufficient. The aim of this study is to address this with a multi-center design and large sample size.

Methods: This is a prospective, multi-center, and randomized controlled clinical trial. A total of 1400 nulliparous women with a singleton pregnancy experiencing natural childbirth from 14 hospitals will be enrolled and randomly allocated to either an intervention group or a control group in a 1:1 ratio. Subjects in the control group will only receive routine postpartum care. In addition to routine postpartum care, the subjects in the intervention group will be administered a 4-hour acupoint hot compress with a constant temperature of 45 ± 2 °C respectively within 30 minutes after delivery, 24 hours and 48 hours after delivery. The primary outcome will be the time elapsed from delivery to the first urination. The secondary outcomes will be postpartum uterine contraction pain intensity, the Edinburgh Postnatal Depression Scale for screening postpartum depression and the assessment of lactation including recording the lactation initiation time, postpartum diet, appetite, weight, neonatal weight. Discussion: These results will provide evidence for obstetricians and parturients on considering nonpharmacologic and noninvasive intervention in early puerperal rehabilitation.

Keywords: Acupoint hot compress, Early puerperal rehabilitation, Study protocol, Randomized controlled clinical trial

1. Introduction

Early puerperium is the period of adjustment after delivery, which extends until the first week postpartum [1–3]. World Health Organization guideline for postnatal care recommends that mothers and newborns should receive care at least 24 hours after birth including assessment of micturition, urinary incontinence and bowel function, healing of any perineal wound, fatigue, pain, uterine tenderness and lochia, breastfeeding progress and emotional well-being [4]. These issues can interfere with a woman’s ability to care for herself and her infant [5, 6].

Traditional Chinese medicine, with its unique theory system and long-term clinical practice, has significant potential for early puerperium rehabilitation. Acupuncture and electroacupuncture have been shown to have positive significant effects in facilitating the first urination following vaginal delivery [7, 8]. Hot compress, as a nonpharmacologic and noninvasive intervention, can effectively avoid the potential side effects of medications [9, 10]. Acupoint hot compress, with a combination of acupoints and natural physical agent heat, is more acceptable, both physically and mentally for puerperal patients and their family due to the non-invasive character [9, 11]. Hot compress has been widely used by midwives to decrease the events of genital trauma and to improve the comfort during delivery [12]. However, little evidence could be found regarding the clinical practice of using an acupoint hot compress for women during early puerperal rehabilita-
Table 1. SPIRIT schedule of enrolment, interventions, and assessments.

| Study period | Enrolment Allocation | Post-allocation | Follow-up |
|--------------|---------------------|-----------------|-----------|
| Timepoint    | 0                   | t₁ t₂ t₃        | t₁ t₂ t₃ t₄ |
| (After delivery) | Within 30 minutes | 24 hours 48 hours 6 ± 0.5 hours 28 ± 0.5 hours 52 ± 0.5 hours 76 ± 0.5 hours |
| Enrolment    |                      |                 |           |
| Eligibility screen | X             |                 |           |
| Informed consent | X              |                 |           |
| Randomization | X                   |                 |           |
| Allocation   |                     | X               |           |
| Interventions| Routine postpartum care & Acupoint hot compress | X X X | |
| Assessments  | Postpartum urinary retention | X | |
|              | Postpartum uterine contraction pain (VAS) | X X X X | |
|              | Emotions symptoms (EPDS) | X | |
|              | Lactation | X X X | |

VAS, visual analogue scale; EPDS, Edinburgh postnatal depression scale.

2. Materials and methods

2.1 Objectives

The trial is designed to evaluate the effects of an acupoint hot compress in reducing the incidence of postpartum urinary retention, relieving postpartum uterine contraction pain, preventing emotional disorders, and promoting lactation.

2.2 Trial registration

The final protocol version is 2.1, dated 25 August 2020. The protocol was approved by the Ethics Committee of Women’s Hospital, School of Medicine, Zhejiang University with the Approval No. IRB-20200223-R on 7 September 2020. The trial was registered at World Health Organization International Clinical Trial Registration Platform, Chinese Clinical Trial Registry (Chictr) with the registration number ChiCTR2000038417. Registered 22 September 2020, [http://www.chictr.org.cn/showproj.aspx?proj=57108](http://www.chictr.org.cn/showproj.aspx?proj=57108).

2.3 Study design

The study is a prospective, multi-center, and randomized controlled clinical trial, which will be conducted in China. All enrolled subjects will be comprehensively briefed on the study, including the purpose, procedure, and possible risks of the study. Informed consent will be obtained from all participants before the start of this study. The demographic data, information about pregnancy, delivery, and newborns will be recorded as baseline data. When the protocol need to be modified, the implementation will be started only after the corresponding revised parts approved by the ethics committee, and all research centers, investigators and the funder are notified at the same time. The study will follow the Code of Ethics of the World Medical Association (Declaration of Helsinki). This protocol is compliant with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) [13] statement (Table 1) and the Consolidated Standards of Reporting Trials (CONSORT) [14] guidelines (Fig. 1).

2.4 Recruitment

The study will be conducted in 14 hospitals in China: Women’s Hospital, School of Medicine, Zhejiang University; Tongde Hospital of Zhejiang Province; Hangzhou First People’s Hospital; The First Affiliated Hospital of Wenzhou Medical University; Yiwu Maternity and Child Health Care Hospital; Jiaxing Maternity and Child Health Care Hospital; Zhejiang Xiaoshan Hospital; Zhoushan Women and Children Hospital; Shaoxing Maternity and Child Hospital; The Women & Children Hospital of Dongyang; Ruian People’s Hospital; Cixi Maternity and Child Health Care Hospital; Wenling Maternity and Child Health Care Hospital and Xianju People’s Hospital. Posters will be placed in each institution’s bulletin board to recruit subjects. No specific culture, race, or socio-economic group will be targeted or restricted from the recruitment. On submission, the study is now in the process of patient recruitment and the first patient was recruited on 17 January 2021.

2.5 Participants

2.5.1 Inclusion criteria

(1) Age is more than 18 years old;
(2) Nulliparous women with a singleton pregnancy;
(3) Gestational age of delivery is 37–42 weeks;
(4) Parturient undergoing vaginal delivery;
(5) Breastfeeding;
(6) Provision of the signed informed consent.

2.5.2 Exclusion criteria

1. Termination of pregnancy due to fetal malformation or stillbirth;
2. Family history of mental illness or tumor;
3. Mental and psychological diseases, traumatic events, or communication barriers;
4. Pre-pregnancy central nervous system diseases, internal and surgical diseases, breast dysplasia, urogenital related diseases, infectious diseases, and long-term drug treatment;
5. Skin damage, ulceration, sensory disorders, acute closed injury, suppurative infection, acute inflammation and other infectious diseases, skin diseases, severe diabetes, high fever and allergy to product materials;
6. Incomplete provision of information.

2.5.3 Subject withdrawal

On request, the enrolled subjects can withdraw from the clinical trial at any stage of the study.

2.5.4 Subject drop-out and discontinuation

1. Implementation of rescue due to postpartum hemorrhage, eclampsia, or other obstetric conditions;
2. Change of vaginal delivery to cesarean section;
3. Infection during delivery;
4. Indwelling catheter and the need to use diuretics due to disease within 6 hours after delivery;
5. Degree III laceration above the perineal fissure;
6. Neonatal transfer after birth;
7. The investigator can terminate the subject from continuing the clinical trial at any stage, if the investigator deems that the risks of continuing the clinical trial outweigh the benefits;
8. Subject’s poor compliance to this trial.
2.6 Sample size calculation

This study will use a superiority design. According to the pilot study, the incidence rate of urinary retention was 7.7% in the intervention group and 25.7% in the control group. Assuming a 1:1 ratio of intervention to control group and using a one-sided test, a significance level (α) of 0.025 and a power (1-β) of 80% and a possible drop-out rate of 20%, the estimated sample size is 700 cases in each group with 50 cases at each center in each group. Intervention and control groups would require a total sample size of 1400 cases.

2.7 Randomization and blinding

Eligible subjects will be randomly assigned to the intervention group or control group in a ratio of 1:1. The randomization number sequence will be generated with the software SAS 9.4 (SAS Institute, Cary, NC, USA) by an independent statistician. Randomization number sequence will be stored by a non-involved investigator. The design is open label, but the outcome assessors and statisticians who are blinded to group allocation will be responsible for collecting and analyzing the data, respectively.

2.8 Interventions

2.8.1 Control group

The subjects in the control group will only receive routine postpartum care, including observing vital signs (blood pressure, heart rate, pulse, temperature and oxygen saturation of blood), monitoring amount of vaginal bleeding and discharge of lochia, palpating fundus and cleansing vulva [15].

2.8.2 Intervention group

In addition to routine postpartum care, the subjects in the intervention group will be administered a 4-hour acupoint hot compress with a constant temperature of 45 ± 2 °C respectively within 30 minutes after delivery (Intervention I), 24 hours (Intervention II), and 48 hours (Intervention III) after delivery. Hot compress will be performed using a licensed Class II medical device, Hu-Chao-Nuan-Gong-Bao (produced by Jiangxi Shenghe Industrial Development Co., Ltd., Nanchang, China with a license No. 20192090292). Four hot cores of Model A (13 × 10 cm) and another two hot cores of Model B (16 × 9 cm) are included in the licensed device. The material layer of a hot core consists of iron powder, water, activated carbon and inorganic salts, which are put into a sealed inner bag with a specific proportion. A specific water vapor transmission rate and a specific oxygen transmission rate of the air-permeable layer can keep a constant temperature (Fig. 2).

The selection of acupoints is based on the clinical experiences of our hospital and the consultation with 10 experts in Chinese medicine. The location of acupoints is described as per the Nomenclature and Location of Acupuncture Points (National Standard of People’s Republic of China, 2006 [GB/T 12346-2006]) [16]. As seen in Fig. 3, during Intervention I (within 30 minutes after delivery), two hot cores (Model A) will be respectively administered on Shenque (RN8, in the center of the umbilicus) and Baliao (BL31-34, in the region of the sacrum, between the posterior-superior iliac spine and the posterior midline, in the 1st,
Fig. 3. Acupoints. (a) Shenque (RN8), in the center of the umbilicus. (b) Balliao (BL31-34), in the region of the sacrum, between the posterior-superior iliac spine and the posterior midline, in the 1st, 2nd, 3rd and 4th posterior sacral foramen, from top to bottom are Shangliao, Ciliao, Zhongliao, and Xialiao. (c) Yongquan (KI1), on the sole, in the depression when the foot is in plantar flexion, and in the anterior depression when the foot is flexed, approximately at the junction of the anterior 1/3 and posterior 2/3 of the sole.

2nd, 3rd and 4th posterior sacral foramen, from top to bottom are Shangliao, Ciliao, Zhongliao, and Xialiao). Two hot cores (Model B) will be respectively administered on Bilateral Yongquan (KI1, on the sole, in the depression when the foot is in plantar flexion, and in the anterior depression when the foot is flexed, approximately at the junction of the anterior 1/3 and posterior 2/3 of the sole). During Intervention II and III (24 hours and 48 hours after delivery), only one hot core (Model A) will be administered on Shenque (RN8).

2.9 Outcomes measures

2.9.1 Primary outcome

Assessment of postpartum urinary retention will be conducted at 6 ± 0.5 hours after delivery, and the time of the first urination after delivery will be recorded [4, 17–19].

2.9.2 Secondary outcomes

Postpartum uterine contraction pain: The visual analogue scale (VAS) will be used to evaluate the postpartum uterine contraction pain intensity: Using a horizontal ruler of 100
mm, "0" representing no pain and "100" representing unbearable pain. The pain VAS intensity will be respectively measured at 6 ± 0.5 hours, 28 ± 0.5 hours, 52 ± 0.5 hours, and 76 ± 0.5 hours after delivery [20].

Emotion symptoms: The Edinburgh Postnatal Depression Scale (EPDS) will be used for screening the depressive symptoms at 76 ± 0.5 hours after delivery. It contains 10-item: pessimism, lack of interest, self-blame, worry, fear, impaired ability, sleep disorder, sadness, tearfulness, self-injury/suicidal ideation, each of which is scored from 0 to 3 [6].

Lactation: Assessment of lactation will be conducted at 28 ± 0.5 hours, 52 ± 0.5 hours, and 76 ± 0.5 hours after delivery, including recording the lactation initiation time, postpartum diet, appetite, weight, neonatal weight [21, 22].

2.10 Safety

The medical device for hot compress used in the present study is licensed by Medical Products Administration (Jiangxi Province, China) with a Licensed Number 20192090292. No adverse events (AEs) has occurred. In the pilot study, the safety evaluation was also comprehensively followed, and no AEs occurred. In the study, the participants with sensory disorders have been excluded. Prior to obtaining consent from the participants, the potential AEs have been explained to the participants. AEs will be monitored and recorded in detail throughout the whole study period.

2.11 Data collection, management and monitoring

All the investigators will receive standard training and will operate strictly according to the standard operating procedure. Double data entry will be applied to ensure the data entry accuracy. A data monitoring committee will be set up before the first enrolment of participants. The original data will be collected and recorded in the form of case report forms (CRFs). Each participant and the investigator will sign and record the date on CRFs, which will be maintained in a secure location. All the data and the CRFs during the current study are available from the corresponding author on reasonable requests. After publication of the study, all the relevant data will be stored for 3 years in Women’s Hospital, School of Medicine, Zhejiang University.

2.12 Statistical methods

Statistical analysis will be performed by independent analysts by using SAS 9.4 statistical analysis software. All the analyses will be based on an intention-to-treat principle. Continuous data will be represented by the average, standard deviation, median, minimum and maximum value; categorical data will be represented by the number and percentages. Continuous data will be analyzed using the t test or one-way ANOVA; Wilcoxon-Mann-Whitney test will be used when necessary. Categorical data will be analyzed using the chi-square test or Fisher’s exact test. The logistic regression analyses will also be used to find the relationship between independent variables. p < 0.05 will be considered statistically significant.

3. Discussion

Postpartum urinary retention (PUR) is the inability to void spontaneously within 6 hours of vaginal delivery [17], and its prevalence varies from 1.5% to 45% [23]. Episiotomy is a key factor, instead of an independent one, for increasing the incidence rates of PUR after vaginal delivery [24, 25]. PUR increases the risk of permanent voiding difficulties, recurrent urinary tract infections, and urinary incontinency [26, 27], which, in turn, increases the risk of postpartum depression [28]. Pregnancy and early puerperium represent a sensitive period for the human maternal brain [29]. The prevalence of postpartum depression varies from 1.9% to 82.1% in developing countries and from 5.2% to 74.0% in developed countries [30]. Nearly 60.5% of women who experience postpartum depressive symptoms do not seek help [31]. It was reported the prevalence of having a clinical diagnosis of any anxiety disorder was 9.6% at 5–12 weeks postpartum, 9.9% at 1–24 weeks postpartum and 9.3% at >24 weeks postpartum [32]. The prevalence of a generalized anxiety disorder was 6.7% at 5–12 weeks postpartum, 5.7% at 1–24 weeks postpartum, and 4.2% at >24 weeks postpartum [32]. Postpartum depression is a frequent comorbidity associated with anxiety in 4.3% of women [6]. Mood disturbances at 3 days postpartum are the best predictor of postpartum depression at 6 weeks postpartum [33]. Moreover, the intense uterine contractions induced by the newborn’s suckling cause intense maternal abdominal pain, which decreases the amount of breast stimulation and eventually decreases the milk supply [21, 34, 35]. In a survey, nearly 90% of new mothers reported that uterine contraction pain possess negative effects on the newborn care and disturb daily living [36]. However, to maintain a strong uterine myometrium toxicity in the first few days of postpartum period may help decrease postpartum hemorrhage and promote uterine involution [37].

Parasympathetic nerve can innervate bladder, internal sphincter and myometrial activity [38, 39]. Breastfeeding is associated with the increased parasympathetic nervous system modulation, decreased neuroendocrine response to stressors and fewer depressive symptoms [40]. Thermotherapy to the lumbar or abdominal region have been found to improve the peripheral hemodynamics and inhibit sympathetic nerve activity, resulting in parasympathetic nerve activity dominance [41]. Heat conduction or hot compress in some specific parts of human body surface can promote local blood circulation, improve tissue metabolism, alleviate pain and relieve anxiety [42, 43]. Anatomically, Baliao face four pairs of posterior sacral foramen, and there are sacral nerves in the deep part. Stimulation of sacral nerve root by hot compress may affect the area dominated by sacral nerve, including urinary system, reproductive system and anal intestine in pelvic cavity. Acupoint hot compress may also affect the functions of bladder and urethra through the urination center. The regulatory effects of acupoint hot compress at lumbosacral points on bladder is related to pudendal nerve, pelvic nerve and other peripheral nerves. However, the pathway
and mechanism of its action are still unclear. Acupuncture appears to be effective for postpartum depression with respect to certain outcomes [44]. However, the evidence thus far is inconclusive and the mechanism is still to be clarified. Moreover, few study has been conducted on the effects and mechanism of hot compress on the postpartum uterine contraction pain and lactation. The mechanism is supposed to be associated with increasing the peripheral blood circulation, regulating the autonomic nerve activity and improving neuroendocrine regulation.

Based on clinical practice, the present study is designed to explore whether acupoint hot compress could be beneficial in decreasing the incidence of PUR, relieving the postpartum uterine contraction pain, preventing emotional disorders and promoting lactation in early puerperium.

The findings of the prospective, multi-center and randomized controlled clinical trial will provide evidences for the obstetricians and parturients on considering the non-pharmacologic and noninvasive interventions of early puerperal rehabilitation.

Abbreviations

CONSORT, the Consolidated Standards of Reporting Trials; SPIRIT, Standard Protocol Items Recommendations for Intervention Trials; VAS, Visual analogue scale; EPDS, Edinburgh Postnatal Depression Scale; AEIs, adverse events; CRFs, case report forms; PUR, Postpartum urinary retention.

Author contributions

FQ conceived the study, designed the study protocol, and revised the manuscript. YHZ drafted the manuscript. AHZ and CL contributed to collect and analyze the data of the pilot study. NR, MSL, XMH, HWL and RZ edited and improved the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The protocol was approved by the Ethics Committee of Women’s Hospital, School of Medicine, Zhejiang University (No. IRB-20200223-R). Written informed consent will be obtained from all participants at the beginning of the study.

Acknowledgment

The authors would like to thank Yi Zhao (Clinical Trial Center of Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China), Jing Zhao (Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China), and Xiaqiu Wu (School of Public Health, Zhejiang Chinese Medical University, Hangzhou, China) for their valuable comments.

Funding

This study was supported by Association for Maternal and Child Health, Zhejiang Province, China (ZY2020-01). The funder is responsible for the administrative and financial management of the study, and not involved in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Conflict of interest

The authors declare no conflict of interest. MSL, FQ and HWL are the Guest Editors of this journal, given their roles as Guest Editors, MSL, FQ and HWL had no involvement in the peer-review of this article and have no access to information regarding its peer-review.

References

[1] ACOG Committee Opinion No. 736: Optimizing Postpartum Care. Obstetrics & Gynecology. 2018; 131: e140–e150.
[2] Kristoschek J, Moreira de Sá R, Silva F, Vellarde G. Ultrasonographic Evaluation of Uterine Involution in the Early Puerperium. Revista Brasileira De Ginecologia E Obstetricia/ RBGO Gynecology and Obstetrics. 2017; 39: 149–154.
[3] Xue FX, Ma YY. Obstetrics and Gynecology. In Li XT. (ed.) Puerperium (pp. 621–626). Beijing: Tsinghua University Press. 2017.
[4] WHO recommendations on maternal health: guidelines approved by the WHO Guidelines Review Committee (Updated May 2017). Postnatal Care (pp. 16–19). Geneva: World Health Organization. 2017.
[5] ACOG Committee Opinion No. 742: Postpartum Pain Management. Obstetrics & Gynecology. 2017; 132: e35–e43.
[6] Meltzer-Brody S, Howard LM, Bergink V, Vigod S, Jones I, Munk-Olsen T, et al. Postpartum psychiatric disorders. Nature Reviews Disease Primers. 2018; 4: 18022.
[7] Sudhakaran P. Urinary Retention in Pregnancy and Puerperium: Acupuncture Treatment. Medical Acupuncture. 2019; 31: 269–273.
[8] Wang X, Gong J, Li S, Han M. Acupuncture Compared with Intramuscular Injection of Neostigmine for Postpartum Urinary Retention: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine. 2018; 2018: 2072091.
[9] Akbarzadeh M, Vaziri F, Farahmand M, Masoudi Z, Amooee S, Zare N. The Effect of Warm Compress Bistage Intervention on the Rate of Epiotomy, Perineal Trauma, and Postpartum Pain Intensity in Primiparous Women with Delayed Valsalva Maneuver Referring to the Selected Hospitals of Shiraz University of Medical Sciences in 2012–2013. Advances in Skin & Wound Care. 2016; 29: 79–84.
[10] Liu Z, Liu B, Lin X. Kinematic effect of Chinese herbal fomentation on patients with chronic neck pain. Chinese Journal of Integrative Medicine. 2014; 20: 917–922.
[11] Yin J, Nisar A, Waqas A, Guo Y, Qi WL, Wang D, et al. Psychosocial interventions on perinatal depression in China: A systematic review and meta-analysis. Journal of Affective Disorders. 2020; 271: 310–327.
[12] Sanders J, Peters TJ, Campbell R. Techniques to reduce perineal pain during spontaneous vaginal delivery and perineal suturing: a UK survey of midwifery practice. Midwifery. 2005; 21: 154–160.
[13] Chan A, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krkleza-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine. 2013; 158: 200–207.
[14] Moher D, Hopewell S, Schulz FK, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. British Medical Journal. 2010; 340: c686.
[15] Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association; Chinese Society of Perina-
Huang L, Zhao J, Wu Z, Wu X, Tan Y. Editorial explanation on Bullough CH, Msuku RS, Karonde L. Early suckling and postpartum urinary retention. Obstetrics and Gynecology. 2005; 106: 602–606.

Cavkaytar S, Kokanah MK, Baylas A, Topcu HO, Laleli B, Taşçı Y. Postpartum urinary retention after vaginal delivery: Assessment of risk factors in a case-control study. Journal of the Turkish German Gynecological Association. 2014; 15: 140–143.

Gu SF, Li MQ, Li Y, Chen M, Han LL. Acupuncture at Ciliao (BL 32) for prevention of postpartum urinary retention in elderly parturient women: a randomized controlled trial. Zhongguo Zhen Jiu. 2020; 40: 611–614. (In Chinese)

Olsén MF, Elden H, Janson ED, Lilja H, Stener-Victorin E. A comparison of high- versus low-intensity, high-frequency transcutaneous electric nerve stimulation for painful postpartum uterine contractions. Acta Obstetricia et Gynecologica Scandinavica. 2007; 86: 310–314.

Kellams A, Harrel C, Omage S, Gregory C, Rosen-Carole C. ABM Clinical Protocol #3: Supplementary Feedings in the Healthy Term Breastfed Neonate, Revised 2017. Breastfeeding Medicine. 2017; 12: 188–198.

Hartmann P, Cregan M. Lactogenesis and the effects of insulin-dependent diabetes mellitus and prematurity. The Journal of Nutrition. 2001; 131: 3016S–3020S.

Mulder FEM, Schoffelmeer MA, Limpens J, Van der Post JAM, Roovers JPPWR. Postpartum urinary retention: a systematic review of adverse effects and management. International Urogynecology Journal. 2014; 25: 1605–1612.

Mulder FEM, Schoffelmeer MA, Hakvoort RA, Limpens J, Mol BWJ, van der Post JAM, et al. Risk factors for postpartum uterine retention: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics and Gynecology. 2012; 119: 1440–1446.

Carley ME, Carley JM, Vasdev G, Lesnick TG, Webb MJ, Ramin KD, et al. Factors that are associated with clinically overt postpartum urinary retention after vaginal delivery. American Journal of Obstetrics and Gynecology. 2002; 187: 430–433.

Rizvi RM, Khan ZS, Khan Z. Diagnosis and management of postpartum urinary retention. International Journal of Gynaecology and Obstetrics. 2005; 91: 71–72.

Groutz A, Levin I, Gold R, Pauzner D, Lessing JB, Gordon D. Protracted postpartum urinary retention: the importance of early diagnosis and timely intervention. Neuurology and Urodynamics. 2011; 30: 83–86.

Fritel X, Tsegan YE, Pierre F, Saurel-Cubizolles M. Association of postpartum depressive symptoms and urinary incontinence. A cohort study. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2016; 198: 62–67.